Published in final edited form as:

J Proteome Res. 2019 May 03; 18(5): 2088–2099. doi:10.1021/acs.jproteome.8b00970.

Comparative analysis of the transcriptome and proteome during mouse placental development

Majd Abdulghani^{||,§,⊥}, Gaoyuan Song[‡], Haninder Kaur[§], Justin W. Walley^{||,‡}, and Geetu Tuteja^{*,||,§}

^{||}Interdepartmental Genetics and Genomics, Iowa State University, Ames, IA, 50011-1079, USA.

[§]Department of Genetics, Development, and Cell Biology, Iowa State University, Ames, IA, 50011-1079, USA.

[‡]Department of Plant Pathology and Microbiology, Iowa State University, Ames, IA 50011-1079, USA.

[⊥]Current address: Life Sciences Institute, University of Michigan, Ann Arbor, MI 48109-2216, USA.

Abstract

The condition of the placenta is a determinant of the short- and long-term health of the mother and the fetus. However, critical processes occurring in early placental development, such as trophoblast invasion and establishment of placental metabolism, remain poorly understood. To gain a better understanding of the genes involved in regulating these processes, we utilized a multi-omics approach, incorporating transcriptome, proteome, and phosphoproteome data generated from mouse placental tissue collected at two critical developmental timepoints. We found that incorporating information from both the transcriptome and proteome identifies genes associated with timepoint-specific biological processes, unlike using the proteome alone. We further inferred genes upregulated based on the proteome data but not the transcriptome data at each timepoint, leading us to identify 27 genes that we predict to have a role in trophoblast migration or placental metabolism. Finally, using the phosphoproteome dataset, we discovered novel phosphosites that may play crucial roles in the regulation of placental transcription factors. By generating the largest proteome and phosphoproteome datasets in the developing placenta, and integrating transcriptome analysis, we uncovered novel aspects of placental gene regulation.

Graphical Abstract

*Corresponding author. geetu@iastate.edu. Phone: +1-515-294-3417.

Author Contributions

M.A., G.S. and J.W. prepared samples for the LC/MS-MS run. J.W. and G.S. carried out the database search and FDR filtering of the data from LC/MS-MS. M.A., J.W. and G.T. contributed to data analysis design, and M.A. carried out the analysis. M.A., H.K., J.W. and G.T. contributed to the overall study design and interpretation of results. The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.

Keywords

placenta; trophoblast invasion; proteomics; transcriptomics; phosphoproteomics; multi-omics; mouse; development

INTRODUCTION

Normal placental development is essential for a successful pregnancy and fetal growth, as the placenta performs the role of several organ systems¹. It provides nutrients and oxygen to the growing fetus, eliminates waste from the fetal blood supply, and secretes hormones that maintain the pregnancy¹. Soon after implantation, specialized cells of the placenta (trophoblasts) invade the uterine tissue, ensuring attachment of the fetus to the mother¹. Trophoblasts also invade uterine spiral arteries, remodeling them to increase blood supply to the placenta¹. In order to maximize the surface area available for nutrient and gas exchange between maternal and fetal blood, fetal blood vessels within the placenta form a branching structure, known as the villous tree, which is in direct contact with maternal blood¹.

Defects in these early placental processes are linked to multiple disorders. For example, abnormal trophoblast invasion has been associated with preeclampsia (PE)², a hypertensive pregnancy disorder that can cause significant liver and kidney damage and lead to maternal and fetal mortality². In addition, defects in trophoblast invasion or placental metabolism are associated with intrauterine growth restriction (IUGR), where the fetus is too small for gestational age due to a deficient supply of nutrients and oxygen³.

However, it is difficult to access normal human placentas during early development, while trophoblasts are migrating and nutrient transport is being established. Therefore, the mouse is frequently used as a model for understanding placental biology. Although some differences exist, such as in the anatomical structure, mouse placentation shares many

similarities with human placentation⁴. The placentas of both species are classified as hemochorial (fetal cells come in direct contact with maternal blood), and possess invasive subtypes of trophoblasts⁴. Moreover, there are many conserved signaling pathways between them, such as Hypoxia Inducible Factor signaling⁵ and Wnt signaling⁶. Thus, we utilized the mouse model to investigate the molecular pathways involved in early placental development.

At embryonic day (E)7.5 in mouse, blood flow has not yet been established and invasion-associated genes, such as Matrix metalloproteinase-9 (Mmp9)⁷, are highly expressed. On the other hand, metabolism of nutrients from maternal blood occurs after blood flow establishment, around E9.5⁸. Many genes are important for regulating migration and metabolism in the placenta. For example, MMPs have a role in trophoblast migration⁹, and peroxisome proliferator-activated receptor- γ (PPAR γ) has a role in metabolism¹⁰. However, we still do not fully understand how trophoblast migration and placental metabolism are regulated on a genomic level.

Most genome-wide investigations in the placenta employ transcriptome profiling, because it is sensitive and cost-effective. However, studies have shown that mRNA may not serve as a reliable proxy for protein expression^{11–15}. Nevertheless, few studies have been carried out in the placenta that integrate proteome and transcriptome data^{16–18}. Furthermore, despite the importance of posttranslational modifications, such as phosphorylation, in modulating protein function, only two studies have previously profiled the placental phosphoproteome at the level of the entire cell^{19,20}, whereas other publications have focused on phosphorylation of plasma membrane proteins²¹ or of mitochondrial proteins²². None of these studies utilized the phosphoproteome to complement proteome and transcriptome profiling in the developing placenta.

We used transcriptomics, proteomics, and phosphoproteomics to identify expression differences between the E7.5 and E9.5 placenta. We identified upregulated proteins that were unchanged at the transcript level, and upregulated transcripts that were unchanged at the protein level. Based on these data, we identified novel genes that we predict to be involved in trophoblast migration and placental metabolism. In addition, we discovered novel phosphorylation events on transcription factors (TFs) known to regulate placental processes. This analysis furthers our understanding of gene expression dynamics in the mouse placenta, reveals novel phosphorylation events, and implicates new candidates that may have a role in trophoblast migration or placental metabolism.

MATERIALS AND METHODS

A list of used materials and reagents can be found in the Supplementary Materials and Methods.

Ethical statement

All animals were treated under protocol 11–14-7898-M approved by the Iowa State University Institutional Animal Care and Use Committee.

Sample collection

Timed-pregnant CD-1 mice were obtained from Charles Rivers Labs and dissected at E7.5 to obtain ectoplacental cones (EPCs) and at E9.5 to obtain placentas as described by Martin and Cockcroft²³. Staging of the mouse embryos was done according to Theiler criteria²⁴. For each biological replicate at E7.5 (3 replicates total), ~60 EPCs were collected and combined from ~6 pregnant mice. Biological replicates did not overlap in any litters. For each biological replicate at E9.5 (3 replicates total), four placentas were collected from one pregnant mouse. The placentas and EPCs were snap frozen in liquid nitrogen and stored at -80°C until extraction.

Sample processing and two-dimensional liquid chromatography coupled with tandem mass spectrometry (2D-LC-MS/MS)

Protein extraction, digestion, tandem mass tag (TMT) labeling, and phosphopeptide enrichment were carried out according to previously published methods^{25–28}. A detailed description of sample processing and 2D-LC-MS/MS is provided in the Supplementary Materials and Methods. The LC parameters for transfer of peptides from the C18 trap column to the Strong Cation Exchange (SCX) column as well as the LC parameters for 2D SCX-Reversed Phase (SCX-RP) separation are provided in Supplementary Tables S1 and S2, respectively.

Database search and false discovery rate (FDR) filtering

The raw data were analyzed using MaxQuant version 1.6.0.16²⁹. Spectra were searched against the GRCm38.p5 Ensembl genome assembly, which was complemented with reverse decoy sequences and common contaminants by MaxQuant. Carbamidomethyl cysteine was set as a fixed modification while methionine oxidation and protein N-terminal acetylation were set as variable modifications. Digestion parameters were set to “specific” and “Trypsin/P;LysC”. Up to two missed cleavages were allowed. A false discovery rate less than 0.01 at both the peptide spectral match and protein identification level was required. The “match between runs” feature of MaxQuant was not utilized. Raw data files and MaxQuant search results have been deposited in the Mass Spectrometry Interactive Virtual Environment (MassIVE) repository: <https://massive.ucsd.edu/ProteoSAFe/static/massive.jsp> with dataset identifier: MSV000082849

Data normalization and filtering

The unmodified proteome (“proteinGroups.txt” MaxQuant output) intensities were normalized using Normalyzer global median intensity (MedI) normalization³⁰. Using Perseus³¹ version 1.6.1.1, we imported the data and then filtered out potential contaminants and reverse peptides. In addition, only proteins that were quantified in all samples were kept in the unmodified proteome (leaving 6,919 proteins). For the phosphoproteome (“Phospho (STY)Sites.txt” MaxQuant output), we used Perseus to filter out contaminants, reverse peptides, and Class II and III phosphosites (localization probability < 0.75) to leave only high confidence phosphorylation events. We then expanded the table before normalizing so as not to introduce bias. Normalization was carried out as it was for the unmodified proteome. We imported the normalized dataset to Perseus and filtered out phosphosites not

quantified in all biological replicates of at least one timepoint (leaving 6,161 Class I phosphosites). We then imputed the missing values from a normal distribution.

Statistical analysis

Perseus was used for statistical analysis and for generating heatmaps. Hierarchical clustering heatmaps were generated using Perseus's default settings (Euclidean distance, average linkage, k-means processing, 300 clusters, and maximum of 10 iterations) after Z-score normalization without grouping the replicates. Pairwise scatterplots with Pearson correlations between biological replicates were generated using the Perseus Multi scatter plot function. Differential expression for both the whole proteome and the phosphoproteome was determined using a two-sample Student's t-test with Perseus's default settings (p-values were corrected with a permutation-based FDR with an FDR cutoff of < 0.05 and 250 permutations). Proteins and phosphosites were considered differentially expressed if the q -value (i.e. FDR) was < 0.05 and the fold change was $\log_2(1.2)$ for upregulation at E7.5 and $-\log_2(1.2)$ for upregulation at E9.5.

Transcriptome analysis

Analyzed mRNA-seq data generated with three biological replicates from each timepoint was obtained from Tuteja et al.³² (two files: one taking into account each isoform and one averaging across isoforms). Fragments per kilobase of transcript per million mapped reads (FPKM) values < 1 were considered not expressed, and the data was filtered to remove genes with FPKM < 1 at both timepoints. Differential expression was determined based on statistical significance (q -value < 0.05) and on a fold change $\log_2(1.5)$ (upregulated at E9.5) or $-\log_2(1.5)$ (upregulated at E7.5).

Proteome-transcriptome integration

The Ensembl IDs provided by MaxQuant were converted to Mouse Genome Informatics (MGI) symbols (provided in the mRNA-seq analysis) using the biomaRt R package³³. Ensembl IDs that were not mapped (~23) were manually converted using the gene name. Venn Diagrams were generated with the VennDiagram R package³⁴.

Functional Enrichment Analysis

WebGestalt³⁵ was used for functional enrichment analysis. The reference gene set was "genome_protein-coding", the Functional database was "geneontology" and the functional database name used was "Biological_Process". Advanced parameters were left as defaults, except that significance level was set to an FDR cutoff of 0.05.

Phosphoproteome analysis

Known phosphosites were identified based on the July 2, 2018 update of the phosphorylation site dataset from PhosphoSitePlus³⁶. Conservation of phosphosites was found by running BLAST on the phosphopeptide sequence (obtained from the "sequence window" column in the "phospho (STY)Sites.txt" file) in Uniprot³⁷.

Kinase motifs were identified on differentially accumulating sites by running our dataset pre-aligned to Serine or Threonine residues on Motif-X³⁸ using the following parameters:

width = 13, occurrences = 20, significance = 0.000001, and the background database was IPI mouse proteome. Following the identification of the motifs, we used literature searches, combined with the Phosida tool³⁹ and Human Protein Reference Database⁴⁰, to identify putative kinases associated with each motif.

RESULTS AND DISCUSSION

Analysis of the mouse placental proteome at E7.5 and E9.5

To identify protein pathways mediating trophoblast migration and placental metabolism, we assayed the mouse placental proteome at two developmental timepoints, E7.5 and E9.5. We extracted proteins from three independent biological replicates per timepoint using urea-based extraction, and digested them into peptides using filter aided sample preparation (FASP)-based on-filter digestion²⁵. The peptides were then labeled with six-plex TMT^{41,42} and a 45 g aliquot of the labeled peptides was used directly to quantify protein abundance (i.e. non-modified proteome) by 2D-LC-MS/MS (Supplementary Scheme S1). With stringent FDR cutoffs (0.01 at both the peptide spectral match and protein identification level), and after removing potential contaminants, reverse peptides, and proteins that were not quantified in all of the samples, we identified 6,919 proteins in the placenta at E7.5 and E9.5 (Figure 1a; Supplementary Table S3). To the best of our knowledge, this is the largest proteome obtained from a placental sample. The previous largest proteome was ~4,700 proteins¹⁷ (Supplementary Table S4). To check the quality of the data, we generated pairwise Pearson correlations between the samples. The average correlation between biological replicates was ~0.998, which demonstrated the high reproducibility of our datasets (Supplementary Figure S1). This was further supported using hierarchical clustering, which resulted in grouping of the biological replicates for each timepoint (Figure 1b).

To determine if there were differences between the proteome at E7.5 and E9.5, we performed differential expression analysis. We designated proteins as differentially expressed if they had a q -value < 0.05 and their fold change was $\log_2(1.2)$ (upregulated at E7.5 and downregulated at E9.5) or $-\log_2(1.2)$ (upregulated at E9.5 and downregulated at E7.5). We identified a total of 1,834 differentially expressed proteins (Supplementary Table S5), of which 799 were upregulated at E7.5 and 1,035 were upregulated at E9.5 (Figure 1c). To gain a better understanding of the timepoint-specific processes, we determined which Gene Ontology Biological Process (GOBP) annotations were enriched in each set of differentially expressed proteins. At E7.5, the upregulated proteins were significantly associated with the process of coagulation (Figure 1d), which can be linked to trophoblast function. For example, trophoblast cells secrete many cytokines, which are known to affect coagulation⁴³, to protect the fetus from local attack⁴⁴. In addition, some hemostatic proteins, such as urokinase-type plasminogen activator (uPA), act to stimulate trophoblast invasion⁴⁵. Finally, the coagulation terms may also reflect the involvement of trophoblasts in maintaining hemostasis at the maternal-fetal interface⁴⁶. Therefore, while the coagulation term is relevant, it is not specific to one function of trophoblasts at E7.5.

The 1,035 proteins upregulated at E9.5 were mainly associated with cellular adhesion and translation (Figure 1d). The enrichment of adhesion terms may be related to branching

morphogenesis of placental villi that occurs at E9.5⁴⁷, or the continuous process of trophoblast migration. Again, while adhesion terms are relevant, they are not specific to one function of trophoblasts at E9.5, and some of the adhesion terms are also significant at E7.5 (Figure 1d).

Comparison of timepoint-specific proteomes and transcriptomes

To complement the proteomic analysis, we utilized mRNA-seq data generated in placenta at the same two timepoints, which we previously published³². We focused this analysis on the 6,170 genes that were detected in both the proteome dataset and the transcriptome dataset. 1,178 of these genes were upregulated at E7.5 at the protein or transcript level (Figure 2a), of which only 21.3% were upregulated at both levels (Figure 2a). At E9.5, 1,295 genes were upregulated at the protein or transcript level (Figure 2b), of which only 24.7% were upregulated at both levels (Figure 2b). These data agree with previous findings that mRNA may not be a reliable proxy for protein levels^{11–15} and that genes can exhibit differential expression at the transcript and/or protein level⁴⁸. There could be many reasons for this discrepancy, such as translational efficiency and protein degradation⁴⁹.

To investigate whether genes that are upregulated at both the transcript and protein levels are related to timepoint-specific functions, we examined their functional annotations. We observed a stronger enrichment of migration terms at E7.5 compared to E9.5 and a stronger enrichment of metabolism terms at E9.5 compared to E7.5 (Figure 2c). Migration terms at E7.5 are more specific than the coagulation terms that were enriched when we only used proteomic data (Figure 1d). As discussed in the previous section, enrichment of coagulation terms can reflect many aspects of placental development at E7.5, unlike migration terms, which are likely specific to only trophoblast migration. Additionally, lipid metabolism terms at E9.5 are more specific to this timepoint than the adhesion terms that were enriched when we only used proteome data (Figure 1d). These results indicate that combining information from the proteome and transcriptome can identify more specific functions related to the timepoints than using data from the proteome alone.

Investigation of differentially expressed proteins unique to the proteome

We next wanted to investigate if genes upregulated only at the protein level included genes previously unknown to be important for specific placental functions. These genes may have been overlooked by other analyses because of their lack of differential expression at the transcript level, which is the most commonly used way to assess global gene expression. To identify potentially novel genes important for placental function at E7.5, we focused on the term “locomotion”, because of its relatedness to cell migration. While this term was not one of the top ten (Figure 1d), it was significant (q -value < 0.05). At E7.5, 39 of the 377 genes upregulated exclusively at the protein level were associated with the “locomotion” term. To increase stringency of which genes were considered exclusively upregulated in the E7.5 proteome, we excluded genes that had any transcript isoforms upregulated at E7.5 (instead of using the average isoform expression per gene). We also excluded genes that were significant at the transcript level, even if they had a low fold-change (instead of only considering genes with fold ≥ 1.5 as significant). This left 30 genes that we were confident were upregulated at E7.5 only at the protein level (Table 1). For 29 of the 30 genes, we were

able to identify literature describing their involvement in migration or invasion in non-placental contexts, such as leukocyte migration or cancer cell invasion. Of those, five were already known or implicated in trophoblast invasion, according to previous studies (Table 1). Our literature search identified no such known roles in the placenta for the remaining 24 genes, even though they were associated with invasion/migration in other contexts (Table 1). These genes are potentially novel regulators of trophoblast migration that could either inhibit or promote the process. While inhibitors of invasion are often secreted by the decidua (the uterine tissue surrounding the placenta and embryo⁵⁰), some, such as Gata3⁵¹ and Timps⁵², are also expressed in trophoblasts. Among the genes we identified, Atp8a1^{53,54} and Coro1a^{55,56} promote cancer and white blood cell migration, respectively, and therefore may also promote trophoblast migration. On the other hand, Usp33 inhibits colorectal⁵⁷ and breast⁵⁸ cancer cell migration, and therefore may also be an inhibitor of trophoblast migration. Additional evidence from the literature also supports our prediction that the genes have a role in trophoblast migration. For example, Lsp1⁵⁹, Snca⁶⁰, and Ppbbp⁶¹ are implicated in PE. In addition, Workalemahu et al.⁶² found SNPs in Prkca that were significantly associated with risk of placental abruption, which has been linked to abnormal trophoblast invasion⁶³.

For genes that were upregulated only at the protein level at E9.5, we focused on the significantly enriched GOBP term, “liver development,” (q -value < 0.05). We focused on this term because the liver plays a central role in metabolism, a process that is more active in the placenta at E9.5, after blood flow establishment. Therefore, genes that are associated with this term may have a function in placental metabolism. Eleven of the 595 genes upregulated exclusively at the protein level at E9.5 were associated with the term. After applying the same stringent filtering criteria we did at E7.5, eight genes remained (Table 2). For four of these eight, we were able to identify literature related to their involvement in metabolism in a non-placental context. While one of these genes, Igf2r, has been associated with metabolic functions in the placenta^{122,123}, three genes, Rps6ka1¹²⁴, Upf2¹²⁵, and Gnpnat1¹²⁶, have a known role in metabolic processes, but have no known role in metabolism in the placenta (Table 2).

Analysis of the mouse placental phosphoproteome at E7.5 and E9.5

Given the critical role of phosphorylation in modulating protein function, we performed phosphoproteome profiling at the two timepoints. For this, 300 g of the pooled TMT-labeled peptides was subjected to phosphopeptide enrichment using Titansphere Phos-TiO₂ beads prior to 2D-LC-MS/MS analysis. To maximize the quality of our dataset, we filtered out potential contaminants, reverse peptides, and phosphosites that were not detected in all biological replicates of at least one timepoint. We quantified the level of 6,161 Class I (localization probability = 0.75), 1,343 Class II (0.75 > localization probability = 0.5), and 44 Class III (localization probability < 0.5) phosphorylation sites arising from 2,140 phosphoproteins (Figure 3a). For further analyses, we only considered the 6,161 Class I (localization probability = 0.75) phosphosites (Supplementary Table S6). To the best of our knowledge, this is the largest scale phosphoproteome in the placenta^{19,21,22}. The reproducibility of our dataset was demonstrated by an average pairwise Pearson correlation of ~0.98 between biological replicates (Supplementary Figure S2) and by the close

clustering of each timepoint's biological replicates (Figure 3b). We identified a total of 1,775 differentially accumulating phosphorylation sites, of which 830 were upregulated at E7.5 and 945 were upregulated at E9.5 (Supplementary Table S7). The majority of the phosphosites were doubly phosphorylated, and only a fraction were triply (or more) phosphorylated (Figure 3c). As expected, most of the phosphorylation events occurred on Serines (S), and only a few were detected on Tyrosines (Y; Figure 3d).

Discovery of novel phosphosites

We next focused on information that can only be provided by the phosphoproteome. When comparing the phosphosites in our dataset to data on PhosphoSitePlus¹²⁸, we found that about 13% (830/6,161) of them were novel phosphosites, previously unknown to be phosphorylated in any mouse tissue (Figure 4a). For unknown sites that were differentially accumulating (see Methods; Supplementary Table S7), we further determined whether any of them were located on placental TFs, and if so, whether the site was conserved in human. The conservation criterion was added because functional phosphorylation events are more likely to be conserved than events without characterized functions¹²⁹. At E7.5, we identified four phosphosites on placental TFs: Ets2 S300, Nfat5 S229, Satb2 S13, and Snai1 S92 (Figure 4b). Snai1 and Nfat5 are implicated in PE^{130,131}, while Ets2 and Satb2 are important for trophoblast stem cell renewal^{132,133}. The sites on Nfat5, Satb2, and Snai1 were previously found to be phosphorylated in human on NFAT5 S229, SATB2 S13, SNAI1 S92, but had no prior evidence of phosphorylation in mouse (Figure 4b).

At E9.5, unknown sites that were differentially accumulating and located on placental TFs were Elf3 S230, Elf3 S232, Elf3 S235, and Zeb1 S1004 (Figure 4b). Elf3 is a member of the Ets TF family, which is important for normal placentation^{134–137}, and is differentially expressed under different placental conditions^{32,110,138,139}. Zeb1 has been implicated in angiogenesis and placental maturation based on its expression patterns¹⁴⁰. Three of the four phosphosites, Elf3 S232, Elf3 S235, and Zeb1 S1004, were previously identified in human (corresponding to ZEB1 S1022, ELF3 S212, and ELF3 S215 in human, respectively; Figure 4b). The novel sites identified in this analysis could play crucial roles in modulating protein function and therefore placental development.

Identification of enriched phosphorylation motifs

Given the importance of kinases in cell signaling and gene expression regulation, we wanted to search for overrepresented phosphorylation motifs among differentially accumulating phosphosites. Using Motif-X³⁸, we found 20 significantly overrepresented motifs among the E7.5 upregulated phosphosites (UpP). One was a phosphothreonine motif, while the rest were centered on phosphoserines (Supplementary Table S8). Among E9.5 UpPs, we identified 31 significantly overrepresented motifs, two of which were centered on phosphothreonines, while the remaining were phosphoserine-centered motifs. (Supplementary Table S8). We were not able to identify overrepresented phosphotyrosine motifs due to their low abundance in the data. We next determined the kinases associated with known motifs using a literature search (Supplementary Table S8). While there were shared motifs between E7.5 and E9.5, such as those for Glycogen synthase kinase 3 (Gsk3), Casein kinase II (Ck2), and Cyclin-dependent kinase (Cdk), there are substrate motifs

unique to each timepoint. For example, the Mitogen-activated kinase substrate motif, Serine-Proline-x-x-Serine-Proline, where x is any amino acid, is only enriched at E7.5; and the substrate motif, Serine-x-x-x-Serine-Serine, for Inhibitor of nuclear factor kappa-B kinase is only enriched at E9.5. These results may indicate that timepoint-specific kinases regulate specific processes in the placenta.

CONCLUSIONS

Our analysis revealed nuanced gene expression regulation in the placenta: we found many upregulated transcripts that were unchanged at the protein level and vice versa. However, genes upregulated at both levels were strongly associated with known timepoint-specific functions, highlighting the importance of incorporating different measurements of gene expression. We utilized the differences between the proteome and the transcriptome to implicate novel genes involved in placental development. Finally, we complemented our analysis with phosphoproteome data, which allowed us to discover novel phosphosites that potentially play important roles in placental development.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

ACKNOWLEDGMENTS

We would like to thank Rebekah Starks for extensive discussions and for providing R code, Ashish Jain for help in statistical analyses, Christian Montes for answering questions and running database searches, and Anmar Arif, for writing some of the R code used in this study.

Funding Sources

This work was supported in part by the Eunice Kennedy Shriver National Institute of Child Health & Human Development of the National Institutes of Health [R00HD079545 to G.T.], the National Institute of General Medical Sciences of the National Institutes of Health [R01GM120316 to J.W.W.], and USDANIFA Hatch [project 3808 to J.W.W.]. M.A. was supported by the Saudi Arabian Cultural Mission, USA. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agency.

ABBREVIATIONS

UP	upregulated protein
UT	upregulated transcript
UpP	upregulated phosphosite
E	embryonic day
FPKM	fragments per kilobase mapped
GOBP	Gene Ontology biological process
S	Serine
T	Threonine

Y Tyrosine
TF transcription factor

REFERENCES

- (1). Benirschke K; Burton GJ; Baergen RN Pathology of the Human Placenta; Springer Science & Business Media, 2012.
- (2). Chaiworapongsa T; Chaemsaitong P; Yeo L; Romero R Pre-Eclampsia Part 1: Current Understanding of Its Pathophysiology. *Nature Reviews Nephrology* 2014, 10 (8), 466–480. 10.1038/nrneph.2014.102. [PubMed: 25003615]
- (3). Pardi G; Marconi AM; Cetin I Placental-Fetal Interrelationship in IUGR Fetuses—A Review. *Placenta* 2002, 23, S136–S141. 10.1053/plac.2002.0802. [PubMed: 11978072]
- (4). Rossant J; Cross JC Placental Development: Lessons from Mouse Mutants. *Nat Rev Genet* 2001, 2 (7), 538–548. 10.1038/35080570. [PubMed: 11433360]
- (5). Fryer BH; Simon MC Hypoxia, HIF and the Placenta. *Cell Cycle* 2006, 5 (5), 495–498. 10.4161/cc.5.5.2497. [PubMed: 16552177]
- (6). Sonderegger S; Pollheimer J; Knöfler M Wnt Signalling in Implantation, Decidualisation and Placental Differentiation – Review. *Placenta* 2010, 31 (10), 839–847. 10.1016/j.placenta.2010.07.011. [PubMed: 20716463]
- (7). Reponen P; Leivo I; Sahlberg C; Apte SS; Olsen BR; Thesleff I; Tryggvason K 92-KDa Type IV Collagenase and TIMP-3, but Not 72-KDa Type IV Collagenase or TIMP-1 or TIMP-2, Are Highly Expressed during Mouse Embryo Implantation. *Dev. Dyn* 1995, 202 (4), 388–396. 10.1002/aja.1002020408. [PubMed: 7626795]
- (8). Silva JF; Serakides R Intrauterine Trophoblast Migration: A Comparative View of Humans and Rodents. *Cell Adh Migr* 2016, 10 (1–2), 88–110. 10.1080/19336918.2015.1120397. [PubMed: 26743330]
- (9). Zhu J-Y; Pang Z-J; Yu Y Regulation of Trophoblast Invasion: The Role of Matrix Metalloproteinases. *Rev Obstet Gynecol* 2012, 5 (3–4), e137–e143. [PubMed: 23483768]
- (10). Jawerbaum A; Capobianco E Review: Effects of PPAR Activation in the Placenta and the Fetus: Implications in Maternal Diabetes. *Placenta* 2011, 32 Suppl 2, S212–217. 10.1016/j.placenta.2010.12.002. [PubMed: 21194748]
- (11). Schwanhäusser B; Busse D; Li N; Dittmar G; Schuchhardt J; Wolf J; Chen W; Selbach M Global Quantification of Mammalian Gene Expression Control. *Nature* 2011, 473 (7347), 337–342. 10.1038/nature10098. [PubMed: 21593866]
- (12). Ly T; Ahmad Y; Shlien A; Soroka D; Mills A; Emanuele MJ; Stratton MR; Lamond AI A Proteomic Chronology of Gene Expression through the Cell Cycle in Human Myeloid Leukemia Cells. *eLife* 2014, 3 10.7554/eLife.01630.
- (13). Ghaemmaghami S; Huh W-K; Bower K; Howson RW; Belle A; Dephoure N; O'Shea EK; Weissman JS Global Analysis of Protein Expression in Yeast. *Nature* 2003, 425 (6959), 737–741. 10.1038/nature02046. [PubMed: 14562106]
- (14). Walley JW; Sartor RC; Shen Z; Schmitz RJ; Wu KJ; Urich MA; Nery JR; Smith LG; Schnable JC; Ecker JR; et al. Integration of Omic Networks in a Developmental Atlas of Maize. *Science* 2016, 353 (6301), 814–818. 10.1126/science.aag1125. [PubMed: 27540173]
- (15). Ghazalpour A; Bennett B; Petyuk VA; Orozco L; Hagopian R; Mungrue IN; Farber CR; Sinsheimer J; Kang HM; Furlotte N; et al. Comparative Analysis of Proteome and Transcriptome Variation in Mouse. *PLOS Genetics* 2011, 7 (6), e1001393 10.1371/journal.pgen.1001393. [PubMed: 21695224]
- (16). Sui L; An L; Tan K; Wang Z; Wang S; Miao K; Ren L; Tao L; He S; Yu Y; et al. Dynamic Proteomic Profiles of in Vivo- and in Vitro-Produced Mouse Postimplantation Extraembryonic Tissues and Placentas. *Biol. Reprod* 2014, 91 (6), 155 10.1095/biolreprod.114.124248. [PubMed: 25320150]
- (17). Cox B; Kotlyar M; Evangelou AI; Ignatchenko V; Ignatchenko A; Whiteley K; Jurisica I; Adamson SL; Rossant J; Kislinger T Comparative Systems Biology of Human and Mouse as a

Tool to Guide the Modeling of Human Placental Pathology. *Mol Syst Biol* 2009, 5, 279 10.1038/msb.2009.37. [PubMed: 19536202]

- (18). Cox B; Sharma P; Evangelou AI; Whiteley K; Ignatchenko V; Ignatchenko A; Baczyk D; Czik M; Kingdom J; Rossant J; et al. Translational Analysis of Mouse and Human Placental Protein and MRNA Reveals Distinct Molecular Pathologies in Human Preeclampsia. *Mol Cell Proteomics* 2011, 10 (12), M111.012526. 10.1074/mcp.M111.012526.
- (19). Lee H-J; Jeong S-K; Na K; Lee MJ; Lee SH; Lim J-S; Cha H-J; Cho J-Y; Kwon J-Y; Kim H; et al. Comprehensive Genome-Wide Proteomic Analysis of Human Placental Tissue for the Chromosome-Centric Human Proteome Project. *J. Proteome Res* 2013, 12 (6), 2458–2466. 10.1021/pr301040g. [PubMed: 23362793]
- (20). Kawahara R; Rosa-Fernandes L; Santos A. F. dos; Bandeira CL; Dombrowski JG; Souza RM; Fonseca M. P. da; Festuccia WT; Labriola L; Larsen MR; et al. Integrated Proteomics Reveals Apoptosis-Related Mechanisms Associated with Placental Malaria. *Molecular & Cellular Proteomics* 2018, mcp.RA118.000907. 10.1074/mcp.RA118.000907.
- (21). Wang F; Wang L; Shi Z; Liang G Comparative N-Glycoproteomic and Phosphoproteomic Profiling of Human Placental Plasma Membrane between Normal and Preeclampsia Pregnancies with High-Resolution Mass Spectrometry. *PLOS ONE* 2013, 8 (11), e80480 10.1371/journal.pone.0080480. [PubMed: 24260401]
- (22). Corso M; Thomson M Protein Phosphorylation in Mitochondria from Human Placenta. *Placenta* 2001, 22 (5), 432–439. 10.1053/plac.2001.0672. [PubMed: 11373154]
- (23). Martin P; Cockcroft DL Culture of Postimplantation Mouse Embryos. In *Molecular Embryology: Methods and Protocols*; Sharpe PT, Mason I, Eds.; Methods in Molecular Biology™; Humana Press: Totowa, NJ, 1999; pp 7–22. 10.1385/1-59259-270-8:7.
- (24). Theiler K The House Mouse: Development and Normal Stages from Fertilization to 4 Weeks of Age; Springer-Verlag, 1972.
- (25). Song G; Hsu PY; Walley JW Assessment and Refinement of Sample Preparation Methods for Deep and Quantitative Plant Proteome Profiling. *PROTEOMICS* 2018, 18 (17), 1800220 10.1002/pmic.201800220.
- (26). Song G; McReynolds MR; Walley JW Sample Preparation Protocols for Protein Abundance, Acetylome, and Phosphoproteome Profiling of Plant Tissues. In *Plant Genomics: Methods and Protocols*; Busch W, Ed.; Methods in Molecular Biology; Springer New York: New York, NY, 2017; pp 123–133. 10.1007/978-1-4939-7003-2_9.
- (27). Song G; Brachova L; Nikolau BJ; Jones AM; Walley JW Heterotrimeric G-Protein-Dependent Proteome and Phosphoproteome in Unstimulated Arabidopsis Roots. *PROTEOMICS* 2018, 1800323 10.1002/pmic.201800323.
- (28). Kettenbach AN; Gerber SA Rapid and Reproducible Single-Stage Phosphopeptide Enrichment of Complex Peptide Mixtures: Application to General and Phosphotyrosine-Specific Phosphoproteomics Experiments. *Anal. Chem* 2011, 83 (20), 7635–7644. 10.1021/ac201894j. [PubMed: 21899308]
- (29). Tyanova S; Temu T; Cox J The MaxQuant Computational Platform for Mass Spectrometry-Based Shotgun Proteomics. *Nature Protocols* 2016, 11 (12), 2301–2319. 10.1038/nprot.2016.136. [PubMed: 27809316]
- (30). Chawade A; Alexandersson E; Levander F Normalizer: A Tool for Rapid Evaluation of Normalization Methods for Omics Data Sets. *J. Proteome Res* 2014, 13 (6), 3114–3120. 10.1021/pr401264n. [PubMed: 24766612]
- (31). Tyanova S; Temu T; Sinitcyn P; Carlson A; Hein MY; Geiger T; Mann M; Cox J The Perseus Computational Platform for Comprehensive Analysis of (Prote)Omics Data. *Nature Methods* 2016, 13 (9), 731–740. 10.1038/nmeth.3901. [PubMed: 27348712]
- (32). Tuteja G; Chung T; Bejerano G Changes in the Enhancer Landscape during Early Placental Development Uncover a Trophoblast Invasion Gene-Enhancer Network. *Placenta* 2016, 37 (Supplement C), 45–55. 10.1016/j.placenta.2015.11.001. [PubMed: 26604129]
- (33). Durinck S; Spellman PT; Birney E; Huber W Mapping Identifiers for the Integration of Genomic Datasets with the R/Bioconductor Package BiomaRt. *Nat Protoc* 2009, 4 (8), 1184–1191. 10.1038/nprot.2009.97. [PubMed: 19617889]

- (34). Chen H; Boutros PC VennDiagram: A Package for the Generation of Highly-Customizable Venn and Euler Diagrams in R. *BMC Bioinformatics* 2011, 12, 35 10.1186/1471-2105-12-35. [PubMed: 21269502]
- (35). Wang J; Vasaikar S; Shi Z; Greer M; Zhang B WebGestalt 2017: A More Comprehensive, Powerful, Flexible and Interactive Gene Set Enrichment Analysis Toolkit. *Nucleic Acids Res* 2017, 45 (W1), W130–W137. 10.1093/nar/gkx356. [PubMed: 28472511]
- (36). Hornbeck PV; Zhang B; Murray B; Kornhauser JM; Latham V; Skrzypek E PhosphoSitePlus, 2014: Mutations, PTMs and Recalibrations. *Nucleic Acids Res* 2015, 43 (Database issue), D512–520. 10.1093/nar/gku1267. [PubMed: 25514926]
- (37). Bateman A; Martin MJ; O'Donovan C; Magrane M; Alpi E; Antunes R; Bely B; Bingley M; Bonilla C; Britto R; et al. UniProt: The Universal Protein Knowledgebase. *Nucleic Acids Res* 2017, 45 (D1), D158–D169. 10.1093/nar/gkw1099. [PubMed: 27899622]
- (38). Chou MF; Schwartz D Biological Sequence Motif Discovery Using Motif-x. *Curr Protoc Bioinformatics* 2011, Chapter 13, Unit 13.15–24. 10.1002/0471250953.bi1315s35.
- (39). Gnad F; Gunawardena J; Mann M PHOSIDA 2011: The Posttranslational Modification Database. *Nucleic Acids Res* 2011, 39 (Database issue), D253–260. 10.1093/nar/gkq1159. [PubMed: 21081558]
- (40). Keshava Prasad TS; Goel R; Kandasamy K; Keerthikumar S; Kumar S; Mathivanan S; Telikicherla D; Raju R; Shafreen B; Venugopal A; et al. Human Protein Reference Database—2009 Update. *Nucleic Acids Res* 2009, 37 (Database issue), D767–D772. 10.1093/nar/gkn892. [PubMed: 18988627]
- (41). Thompson A; Schäfer J; Kuhn K; Kienle S; Schwarz J; Schmidt G; Neumann T; Johnstone R; Mohammed AKA; Hamon C Tandem Mass Tags: A Novel Quantification Strategy for Comparative Analysis of Complex Protein Mixtures by MS/MS. *Anal. Chem* 2003, 75 (8), 1895–1904. [PubMed: 12713048]
- (42). Dayon L; Hainard A; Licker V; Turck N; Kuhn K; Hochstrasser DF; Burkhard PR; Sanchez J-C Relative Quantification of Proteins in Human Cerebrospinal Fluids by MS/MS Using 6-Plex Isobaric Tags. *Anal. Chem* 2008, 80 (8), 2921–2931. 10.1021/ac702422x. [PubMed: 18312001]
- (43). Joseph L; Fink LM; Hauer-Jensen M Cytokines in Coagulation and Thrombosis: A Preclinical and Clinical Review. *Blood Coagulation & Fibrinolysis* 2002, 13 (2), 105. [PubMed: 11914652]
- (44). Bowen JM; Chamley L; Mitchell MD; Keelan JA Cytokines of the Placenta and Extra-Placental Membranes: Biosynthesis, Secretion and Roles in Establishment of Pregnancy in Women. *Placenta* 2002, 23 (4), 239–256. 10.1053/plac.2001.0781. [PubMed: 11969335]
- (45). Sood R; Kalloway S; Mast AE; Hillard CJ; Weiler H Fetomaternal Cross Talk in the Placental Vascular Bed: Control of Coagulation by Trophoblast Cells. *Blood* 2006, 107 (8), 3173–3180. 10.1182/blood-2005-10-4111. [PubMed: 16380449]
- (46). Maltepe E; Fisher SJ Placenta: The Forgotten Organ. *Annu. Rev. Cell Dev. Biol* 2015, 31 (1), 523–552. 10.1146/annurev-cellbio-100814-125620. [PubMed: 26443191]
- (47). Cross JC; Simmons DG; Watson ED Chorioallantoic Morphogenesis and Formation of the Placental Villous Tree. *Annals of the New York Academy of Sciences* 2003, 995 (1), 84–93. 10.1111/j.1749-6632.2003.tb03212.x. [PubMed: 12814941]
- (48). Walley J; Xiao Y; Wang J-Z; Baidoo EE; Keasling JD; Shen Z; Briggs SP; Dehesh K Plastid-Produced Interorganelle Stress Signal MEcPP Potentiates Induction of the Unfolded Protein Response in Endoplasmic Reticulum. *PNAS* 2015, 112 (19), 6212–6217. 10.1073/pnas.1504828112. [PubMed: 25922532]
- (49). Plotkin JB Transcriptional Regulation Is Only Half the Story. *Mol Syst Biol* 2010, 6, 406 10.1038/msb.2010.63. [PubMed: 20739928]
- (50). Placentation Fundamentals. In *Comparative Placentation: Structures, Functions and Evolution*; Wooding P, Burton G, Eds.; Springer Berlin Heidelberg: Berlin, Heidelberg, 2008; pp 1–45. 10.1007/978-3-540-78797-6_1.
- (51). Chiu YH; Chen H GATA3 Inhibits GCM1 Activity and Trophoblast Cell Invasion. *Scientific Reports* 2016, 6, 21630 10.1038/srep21630. [PubMed: 26899996]
- (52). Hurskainen T; Höyhty M; Tuuttila A; Oikarinen A; Autio-Harmainen H MRNA Expressions of TIMP-1, -2, and -3 and 92-KD Type IV Collagenase in Early Human Placenta and Decidual

Membrane as Studied by in Situ Hybridization. *J Histochem Cytochem* 1996, 44 (12), 1379–1388. 10.1177/44.12.8985130. [PubMed: 8985130]

- (53). Kato U; Inadome H; Yamamoto M; Emoto K; Kobayashi T; Umeda M Role for Phospholipid Flippase Complex of ATP8A1 and CDC50A Proteins in Cell Migration. *J. Biol. Chem* 2013, 288 (7), 4922–4934. 10.1074/jbc.M112.402701. [PubMed: 23269685]
- (54). Dong W; Yao C; Teng X; Chai J; Yang X; Li B MiR-140–3p Suppressed Cell Growth and Invasion by Downregulating the Expression of ATP8A1 in Non-Small Cell Lung Cancer. *Tumor Biol* 2016, 37 (3), 2973–2985. 10.1007/s13277-015-3452-9.
- (55). Pick R; Begandt D; Stocker TJ; Salvermoser M; Thome S; Böttcher RT; Montanez E; Harrison U; Forné I; Khandoga AG; et al. Coronin 1A, a Novel Player in Integrin Biology, Controls Neutrophil Trafficking in Innate Immunity. *Blood* 2017, 130 (7), 847–858. 10.1182/blood-2016-11-749622. [PubMed: 28615221]
- (56). Föger N; Rangell L; Danilenko DM; Chan AC Requirement for Coronin 1 in T Lymphocyte Trafficking and Cellular Homeostasis. *Science* 2006, 313 (5788), 839–842. 10.1126/science.1130563. [PubMed: 16902139]
- (57). Huang Z; Wen P; Kong R; Cheng H; Zhang B; Quan C; Bian Z; Chen M; Zhang Z; Chen X; et al. USP33 Mediates Slit-Robo Signaling in Inhibiting Colorectal Cancer Cell Migration. *Int. J. Cancer* 2015, 136 (8), 1792–1802. 10.1002/ijc.29226. [PubMed: 25242263]
- (58). Yuasa-Kawada J; Kinoshita-Kawada M; Rao Y; Wu JY Deubiquitinating Enzyme USP33/VDU1 Is Required for Slit Signaling in Inhibiting Breast Cancer Cell Migration. *PNAS* 2009, 106 (34), 14530–14535. 10.1073/pnas.0801262106. [PubMed: 19706539]
- (59). Leavey K; Wilson SL; Bainbridge SA; Robinson WP; Cox BJ Epigenetic Regulation of Placental Gene Expression in Transcriptional Subtypes of Preeclampsia. *Clin Epigenetics* 2018, 10 10.1186/s13148-018-0463-6.
- (60). Junus K; Centlow M; Wikström A-K; Larsson I; Hansson SR; Olovsson M Gene Expression Profiling of Placentae from Women with Early- and Late-Onset Pre-Eclampsia: Down-Regulation of the Angiogenesis-Related Genes ACVRL1 and EGFL7 in Early-Onset Disease. *Mol Hum Reprod* 2012, 18 (3), 146–155. 10.1093/molehr/gar067. [PubMed: 22013081]
- (61). Liu LY; Yang T; Ji J; Wen Q; Morgan AA; Jin B; Chen G; Lyell DJ; Stevenson DK; Ling XB; et al. Integrating Multiple ‘Omics’ Analyses Identifies Serological Protein Biomarkers for Preeclampsia. *BMC Medicine* 2013, 11 (1), 236 10.1186/1741-7015-11-236. [PubMed: 24195779]
- (62). Workalemahu T; Enquobahrie DA; Moore A; Sanchez SE; Ananth CV; Pacora PN; Liang L; Salazar M; Williams MA Genome-Wide and Candidate Gene Association Studies of Placental Abruption. *Int J Mol Epidemiol Genet* 2013, 4 (3), 128–139. [PubMed: 24046805]
- (63). Dommissie J; Tiltman AJ Placental Bed Biopsies in Placental Abruption. *BJOG: An International Journal of Obstetrics & Gynaecology* 1992, 99 (8), 651–654. 10.1111/j.1471-0528.1992.tb13848.x.
- (64). Djaafri I; Khayati F; Menashi S; Tost J; Podgorniak M-P; Sadoux A; Daunay A; Teixeira L; Soulier J; Idbaih A; et al. A Novel Tumor Suppressor Function of Kindlin-3 in Solid Cancer. *Oncotarget* 2014, 5 (19), 8970–8985. [PubMed: 25344860]
- (65). Kiriya K; Hirohashi Y; Torigoe T; Kubo T; Tamura Y; Kanaseki T; Takahashi A; Nakazawa E; Saka E; Ragnarsson C; et al. Expression and Function of FERMT Genes in Colon Carcinoma Cells. *Anticancer Res* 2013, 33 (1), 167–173. [PubMed: 23267142]
- (66). Gruda R; Brown ACN; Grabovsky V; Mizrahi S; Gur C; Feigelson SW; Achdout H; Bar-on Y; Alon R; Aker M; et al. Loss of Kindlin-3 Alters the Threshold for NK Cell Activation in Human Leukocyte Adhesion Deficiency-III. *Blood* 2012, 120 (19), 3915–3924. 10.1182/blood-2012-02-410795. [PubMed: 22983444]
- (67). Wu X; Gallo KA The 18-KDa Translocator Protein (TSPO) Disrupts Mammary Epithelial Morphogenesis and Promotes Breast Cancer Cell Migration. *PLoS One* 2013, 8 (8). 10.1371/journal.pone.0071258.
- (68). Batarseh A; Papadopoulos V Regulation of Translocator Protein 18 KDa (TSPO) Expression in Health and Disease States. *Mol Cell Endocrinol* 2010, 327 (1–2), 1–12. 10.1016/j.mce.2010.06.013. [PubMed: 20600583]

- (69). Gan X; Chen B; Shen Z; Liu Y; Li H; Xie X; Xu X; Li H; Huang Z; Chen J High GPX1 Expression Promotes Esophageal Squamous Cell Carcinoma Invasion, Migration, Proliferation and Cisplatin-Resistance but Can Be Reduced by Vitamin D. *Int J Clin Exp Med* 2014, 7 (9), 2530–2540. [PubMed: 25356106]
- (70). Min SY; Kim HS; Jung EJ; Jung EJ; Jee CD; Kim WH Prognostic Significance of Glutathione Peroxidase 1 (GPX1) Down-Regulation and Correlation with Aberrant Promoter Methylation in Human Gastric Cancer. *Anticancer Res* 2012, 32 (8), 3169–3175. [PubMed: 22843889]
- (71). Bourguignon LYW; Singleton PA; Diedrich F; Stern R; Gilad E CD44 Interaction with Na⁺-H⁺ Exchanger (NHE1) Creates Acidic Microenvironments Leading to Hyaluronidase-2 and Cathepsin B Activation and Breast Tumor Cell Invasion. *J. Biol. Chem* 2004, 279 (26), 26991–27007. 10.1074/jbc.M311838200. [PubMed: 15090545]
- (72). Udabage L; Brownlee GR; Nilsson SK; Brown TJ The Over-Expression of HAS2, Hyal-2 and CD44 Is Implicated in the Invasiveness of Breast Cancer. *Experimental Cell Research* 2005, 310 (1), 205–217. 10.1016/j.yexcr.2005.07.026. [PubMed: 16125700]
- (73). Koral K; Paranjpe S; Bowen WC; Mars W; Luo J; Michalopoulos GK Leukocyte-Specific Protein 1: A Novel Regulator of Hepatocellular Proliferation and Migration Deleted in Human Hepatocellular Carcinoma. *Hepatology* 2015, 61 (2), 537–547. 10.1002/hep.27444. [PubMed: 25234543]
- (74). Cervero P; Wiesner C; Bouissou A; Poincloux R; Linder S Lymphocyte-Specific Protein 1 Regulates Mechanosensory Oscillation of Podosomes and Actin Isoform-Based Actomyosin Symmetry Breaking. *Nature Communications* 2018, 9 (1), 515 10.1038/s41467-018-02904-x.
- (75). O'Neill AK; Gallegos LL; Justilien V; Garcia EL; Leitges M; Fields AP; Hall RA; Newton AC Protein Kinase C α Promotes Cell Migration through a PDZ-Dependent Interaction with Its Novel Substrate Discs Large Homolog 1 (DLG1). *J. Biol. Chem* 2011, 286 (50), 43559–43568. 10.1074/jbc.M111.294603. [PubMed: 22027822]
- (76). Pham TND; Perez White BE; Zhao H; Mortazavi F; Tonetti DA Protein Kinase C α Enhances Migration of Breast Cancer Cells through FOXC2-Mediated Repression of P120-Catenin. *BMC Cancer* 2017, 17 (1), 832 10.1186/s12885-017-3827-y. [PubMed: 29216867]
- (77). Keely PJ; Rusyn EV; Cox AD; Parise LV R-Ras Signals through Specific Integrin Alpha Cytoplasmic Domains to Promote Migration and Invasion of Breast Epithelial Cells. *J. Cell Biol* 1999, 145 (5), 1077–1088. [PubMed: 10352023]
- (78). Sandri C; Caccavari F; Valdembrì D; Camillo C; Veltel S; Santambrogio M; Lanzetti L; Bussolino F; Ivaska J; Serini G The R-Ras/RIN2/Rab5 Complex Controls Endothelial Cell Adhesion and Morphogenesis via Active Integrin Endocytosis and Rac Signaling. *Cell Res* 2012, 22 (10), 1479–1501. 10.1038/cr.2012.110. [PubMed: 22825554]
- (79). Li Y-X; Yu Z-W; Jiang T; Shao L-W; Liu Y; Li N; Wu Y-F; Zheng C; Wu X-Y; Zhang M; et al. SNCA, a Novel Biomarker for Group 4 Medulloblastomas, Can Inhibit Tumor Invasion and Induce Apoptosis. *Cancer Sci* 2018, 109 (4), 1263–1275. 10.1111/cas.13515. [PubMed: 29369502]
- (80). Ge Y; Xu K Alpha-Synuclein Contributes to Malignant Progression of Human Meningioma via the Akt/MTOR Pathway. *Cancer Cell International* 2016, 16 (1), 86 10.1186/s12935-016-0361-y. [PubMed: 27895530]
- (81). Brasher MI; Martynowicz DM; Grafinger OR; Hucik A; Shanks-Skinner E; Uniacke J; Coppelino MG Interaction of Munc18c and Syntaxin4 Facilitates Invadopodium Formation and Extracellular Matrix Invasion of Tumor Cells. *J. Biol. Chem* 2017, 292 (39), 16199–16210. 10.1074/jbc.M117.807438. [PubMed: 28798239]
- (82). Veale KJ; Offenhäuser C; Lei N; Stanley AC; Stow JL; Murray RZ VAMP3 Regulates Podosome Organisation in Macrophages and Together with Stx4/SNAP23 Mediates Adhesion, Cell Spreading and Persistent Migration. *Exp. Cell Res* 2011, 317 (13), 1817–1829. 10.1016/j.yexcr.2011.04.016. [PubMed: 21586284]
- (83). Candy PA; Colley SM; Phillips M; Davidson A; Iacopetta B; Stuart L; Wood B; Redfern A; Leedman PJ SLIRP, a Nuclear Receptor Coregulator, Is a Good Prognostic Factor in Colorectal Cancer. *ENDO Meetings* 2011 10.1210/endo-meetings.2011.PART1.P1.P1-30.

- (84). Deuel TF; Senior RM; Chang D; Griffin GL; Heinrikson RL; Kaiser ET Platelet Factor 4 Is Chemotactic for Neutrophils and Monocytes. *Proc. Natl. Acad. Sci. U.S.A* 1981, 78 (7), 4584–4587. [PubMed: 6945600]
- (85). Fox JM; Kausar F; Day A; Osborne M; Hussain K; Mueller A; Lin J; Tsuchiya T; Kanegasaki S; Pease JE CXCL4/Platelet Factor 4 Is an Agonist of CCR1 and Drives Human Monocyte Migration. *Scientific Reports* 2018, 8 (1), 9466 10.1038/s41598-018-27710-9. [PubMed: 29930254]
- (86). Quemener C; Baud J; Boyé K; Dubrac A; Billottet C; Soulet F; Darlot F; Dumartin L; Sire M; Grepin R; et al. Dual Roles for CXCL4 Chemokines and CXCR3 in Angiogenesis and Invasion of Pancreatic Cancer. *Cancer Res* 2016, 76 (22), 6507–6519. 10.1158/0008-5472.CAN-15-2864. [PubMed: 27634764]
- (87). Jian J; Pang Y; Yan HH; Min Y; Achyut BR; Hollander MC; Lin PC; Liang X; Yang L Platelet Factor 4 Is Produced by Subsets of Myeloid Cells in Premetastatic Lung and Inhibits Tumor Metastasis. *Oncotarget* 2016, 8 (17), 27725–27739. 10.18632/oncotarget.9486.
- (88). Lighvani S; Baik N; Diggs JE; Khaldoyanidi S; Parmer RJ; Miles LA Regulation of Macrophage Migration by a Novel Plasminogen Receptor Plg-RKT. *Blood* 2011, 118 (20), 5622–5630. 10.1182/blood-2011-03-344242. [PubMed: 21940822]
- (89). Miles LA; Lighvani S; Baik N; Khaldoyanidi S; Mueller BM; Parmer RJ New Insights into the Role of Plg-RKT in Macrophage Recruitment. *Int Rev Cell Mol Biol* 2014, 309, 259–302. 10.1016/B978-0-12-800255-1.00005-3. [PubMed: 24529725]
- (90). Guo Q; Jian Z; Jia B; Chang L CXCL7 Promotes Proliferation and Invasion of Cholangiocarcinoma Cells. *Oncol. Rep* 2017, 37 (2), 1114–1122. 10.3892/or.2016.5312. [PubMed: 27959418]
- (91). Tang Z; Yu M; Miller F; Berk RS; Tromp G; Kosir MA Increased Invasion through Basement Membrane by CXCL7-Transfected Breast Cells. *Am. J. Surg* 2008, 196 (5), 690–696. 10.1016/j.amjsurg.2008.08.001. [PubMed: 18954601]
- (92). Zhou X; Zhan W; Bian W; Hua L; Shi Q; Xie S; Yang D; Li Y; Zhang X; Liu G; et al. GOLPH3 Regulates the Migration and Invasion of Glioma Cells Through RhoA. *Biochem. Biophys. Res. Commun* 2013, 433 (3), 338–344. 10.1016/j.bbrc.2013.03.003. [PubMed: 23500462]
- (93). Cai C; Chen Q-B; Han Z-D; Zhang Y-Q; He H-C; Chen J-H; Chen Y-R; Yang S-B; Wu Y-D; Zeng Y-R; et al. MiR-195 Inhibits Tumor Progression by Targeting RPS6KB1 in Human Prostate Cancer. *Clin. Cancer Res* 2015, 21 (21), 4922–4934. 10.1158/1078-0432.CCR-15-0217. [PubMed: 26080838]
- (94). Biswas S; Bachay G; Chu J; Hunter DD; Brunken WJ Laminin-Dependent Interaction between Astrocytes and Microglia. *Am J Pathol* 2017, 187 (9), 2112–2127. 10.1016/j.ajpath.2017.05.016. [PubMed: 28697326]
- (95). Schwab A; Siddiqui A; Vazakidou ME; Napoli F; Böttcher M; Menchicchi B; Raza U; Saatci Ö; Krebs AM; Ferrazzi F; et al. Polyol Pathway Links Glucose Metabolism to the Aggressiveness of Cancer Cells. *Cancer Res* 2018, 78 (7), 1604–1618. 10.1158/0008-5472.CAN-17-2834. [PubMed: 29343522]
- (96). Layton T; Stalens C; Gunderson F; Goodison S; Silletti S Syk Tyrosine Kinase Acts as a Pancreatic Adenocarcinoma Tumor Suppressor by Regulating Cellular Growth and Invasion. *Am J Pathol* 2009, 175 (6), 2625–2636. 10.2353/ajpath.2009.090543. [PubMed: 19893036]
- (97). Luangdilok S; Box C; Patterson L; Court W; Harrington K; Pitkin L; Rhys-Evans P; O-charoenrat P; Eccles S Syk Tyrosine Kinase Is Linked to Cell Motility and Progression in Squamous Cell Carcinomas of the Head and Neck. *Cancer Res* 2007, 67 (16), 7907–7916. 10.1158/0008-5472.CAN-07-0331. [PubMed: 17699797]
- (98). Qiao X; Li C; Li L Spleen Tyrosine Kinase Promotes the Migration and Invasion of Adenoid Cystic Carcinoma via Long Non-Coding RNA H19. *International Journal of Oral and Maxillofacial Surgery* 2017, 46, 132 10.1016/j.ijom.2017.02.459.
- (99). Iqbal AJ; Barrett TJ; Taylor L; McNeill E; Manmadhan A; Recio C; Carmineri A; Brodermann MH; White GE; Cooper D; et al. Acute Exposure to Apolipoprotein A1 Inhibits Macrophage Chemotaxis in Vitro and Monocyte Recruitment in Vivo. *eLife* 5 10.7554/eLife.15190.

- (100). Al-Jarallah A; Chen X; González L; Trigatti BL High Density Lipoprotein Stimulated Migration of Macrophages Depends on the Scavenger Receptor Class B, Type I, PDZK1 and Akt1 and Is Blocked by Sphingosine 1 Phosphate Receptor Antagonists. *PLOS ONE* 2014, 9 (9), e106487 10.1371/journal.pone.0106487. [PubMed: 25188469]
- (101). Wan Y-M; Tian J; Qi L; Liu L-M; Xu N ANXA1 Affects Cell Proliferation, Invasion and Epithelial-Mesenchymal Transition of Oral Squamous Cell Carcinoma. *Exp Ther Med* 2017, 14 (5), 5214–5218. 10.3892/etm.2017.5148. [PubMed: 29201239]
- (102). Bizzarro V; Fontanella B; Franceschelli S; Pirozzi M; Christian H; Parente L; Petrella A Role of Annexin A1 in Mouse Myoblast Cell Differentiation. *J. Cell. Physiol* 2010, 224 (3), 757–765. 10.1002/jcp.22178. [PubMed: 20578244]
- (103). Quinn BJ; Welch EJ; Kim AC; Lokuta MA; Huttenlocher A; Khan AA; Kuchay SM; Chishti AH Erythrocyte Scaffolding Protein P55/MPP1 Functions as an Essential Regulator of Neutrophil Polarity. *Proc. Natl. Acad. Sci. U.S.A* 2009, 106 (47), 19842–19847. 10.1073/pnas.0906761106. [PubMed: 19897731]
- (104). Roh MS; Choi JW; Lee HW; Kwon HC; Park TH; Choi PJ; Lee CH; Cheon BK Differential Expression of CD34 and Smooth Muscle Actin in the Stroma of Small Lung Adenocarcinoma with Mixed Bronchioloalveolar and Invasive Components. *The Korean Journal of Pathology* 2005, 39 (3), 158–163.
- (105). Rai A; Cross JC Three-Dimensional Cultures of Trophoblast Stem Cells Autonomously Develop Vascular-like Spaces Lined by Trophoblast Giant Cells. *Developmental Biology* 2015, 398 (1), 110–119. 10.1016/j.ydbio.2014.11.023. [PubMed: 25499676]
- (106). Yuan L; Shu B; Chen L; Qian K; Wang Y; Qian G; Zhu Y; Cao X; Xie C; Xiao Y; et al. Overexpression of COL3A1 Confers a Poor Prognosis in Human Bladder Cancer Identified by Co-Expression Analysis. *Oncotarget* 2017, 8 (41), 70508–70520. 10.18632/oncotarget.19733. [PubMed: 29050298]
- (107). Qiu F; Sun R; Deng N; Guo T; Cao Y; Yu Y; Wang X; Zou B; Zhang S; Jing T; et al. MiR-29a/b Enhances Cell Migration and Invasion in Nasopharyngeal Carcinoma Progression by Regulating SPARC and COL3A1 Gene Expression. *PLoS One* 2015, 10 (3). 10.1371/journal.pone.0120969.
- (108). Arai KY; Nishiyama T Developmental Changes in Extracellular Matrix Messenger RNAs in the Mouse Placenta during the Second Half of Pregnancy: Possible Factors Involved in the Regulation of Placental Extracellular Matrix Expression. *Biol. Reprod* 2007, 77 (6), 923–933. 10.1095/biolreprod.107.061382. [PubMed: 17881772]
- (109). Jain A; Ezashi T; Roberts RM; Tuteja G Deciphering Transcriptional Regulation in Human Embryonic Stem Cells Specified towards a Trophoblast Fate. *Scientific Reports* 2017, 7 (1), 17257 10.1038/s41598-017-17614-5. [PubMed: 29222466]
- (110). James JL; Hurley DG; Gamage TKJB; Zhang T; Vather R; Pantham P; Murthi P; Chamley LW Isolation and Characterisation of a Novel Trophoblast Side-Population from First Trimester Placentae. *Reproduction* 2015, 150 (5), 449–462. 10.1530/REP-14-0646. [PubMed: 26248480]
- (111). Sang H; Li T; Li H; Liu J Down-Regulation of Gab1 Inhibits Cell Proliferation and Migration in Hilar Cholangiocarcinoma. *PLOS ONE* 2013, 8 (11), e81347 10.1371/journal.pone.0081347. [PubMed: 24312291]
- (112). Paliouras GN; Naujokas MA; Park M Pak4, a Novel Gab1 Binding Partner, Modulates Cell Migration and Invasion by the Met Receptor. *Mol. Cell. Biol* 2009, 29 (11), 3018–3032. 10.1128/MCB.01286-08. [PubMed: 19289496]
- (113). Wang D; Song W; Na Q The Emerging Roles of Placenta-Specific MicroRNAs in Regulating Trophoblast Proliferation during the First Trimester. *Australian and New Zealand Journal of Obstetrics and Gynaecology* 2012, 52 (6), 565–570. 10.1111/j.1479-828X.2012.01481.x. [PubMed: 23046105]
- (114). Järvinen TAH; Prince S Decorin: A Growth Factor Antagonist for Tumor Growth Inhibition .
- (115). Borbely AU; Daher S; Ishigai MM; Mattar R; Sun SY; Knöfler M; Bevilacqua E; Oliveira SF Decorin and Biglycan Immunolocalization in Non-Villous Structures of Healthy and Pathological Human Placentas. *Histopathology* 2014, 64 (5), 616–625. 10.1111/his.12304. [PubMed: 24117774]

- (116). Coan PM; Conroy N; Burton GJ; Ferguson-Smith AC Origin and Characteristics of Glycogen Cells in the Developing Murine Placenta. *Developmental Dynamics* 2006, 235 (12), 3280–3294. 10.1002/dvdy.20981. [PubMed: 17039549]
- (117). Lebrun J-J The Dual Role of TGF in Human Cancer: From Tumor Suppression to Cancer Metastasis .
- (118). Cheng J-C; Chang H-M; Leung PCK Transforming Growth Factor-B1 Inhibits Trophoblast Cell Invasion by Inducing Snail-Mediated Down-Regulation of Vascular Endothelial-Cadherin Protein. *J Biol Chem* 2013, 288 (46), 33181–33192. 10.1074/jbc.M113.488866. [PubMed: 24106276]
- (119). Lash GE; Otun HA; Innes BA; Bulmer JN; Searle RF; Robson SC Inhibition of Trophoblast Cell Invasion by TGFB1, 2, and 3 Is Associated with a Decrease in Active Proteases. *Biol. Reprod* 2005, 73 (2), 374–381. 10.1095/biolreprod.105.040337. [PubMed: 15858216]
- (120). Huang Z; Li S; Fan W; Ma Q Transforming Growth Factor B1 Promotes Invasion of Human JEG-3 Trophoblast Cells via TGF- β /Smad3 Signaling Pathway. *Oncotarget* 2017, 8 (20), 33560–33570. 10.18632/oncotarget.16826. [PubMed: 28432277]
- (121). Lafontaine L; Chaudhry P; Lafleur M-J; Van Themsche C; Soares MJ; Asselin E Transforming Growth Factor Beta Regulates Proliferation and Invasion of Rat Placental Cell Lines. *Biol Reprod* 2011, 84 (3), 553–559. 10.1095/biolreprod.110.086348. [PubMed: 20926802]
- (122). Young LE; Fernandes K; McEvoy TG; Butterwith SC; Gutierrez CG; Carolan C; Broadbent PJ; Robinson JJ; Wilmot I; Sinclair KD Epigenetic Change in *IGF2R* Is Associated with Fetal Overgrowth after Sheep Embryo Culture. *Nature Genetics* 2001, 27 (2), 153–154. 10.1038/84769. [PubMed: 11175780]
- (123). McCann JA; Xu YQ; Frechette R; Guazzarotti L; Polychronakos C The Insulin-Like Growth Factor-II Receptor Gene Is Associated with Type 1 Diabetes: Evidence of a Maternal Effect. *J Clin Endocrinol Metab* 2004, 89 (11), 5700–5706. 10.1210/jc.2004-0553. [PubMed: 15531531]
- (124). Smadja-Lamère N; Shum M; Déleris P; Roux PP; Abe J-I; Marette A Insulin Activates RSK (P90 Ribosomal S6 Kinase) to Trigger a New Negative Feedback Loop That Regulates Insulin Signaling for Glucose Metabolism. *J Biol Chem* 2013, 288 (43), 31165–31176. 10.1074/jbc.M113.474148. [PubMed: 24036112]
- (125). Thoren LA; Nørgaard GA; Weischenfeldt J; Waage J; Jakobsen JS; Damgaard I; Bergström FC; Blom AM; Borup R; Bisgaard HC; et al. UPF2 Is a Critical Regulator of Liver Development, Function and Regeneration. *PLOS ONE* 2010, 5 (7), e11650 10.1371/journal.pone.0011650. [PubMed: 20657840]
- (126). Bacos K; Gillberg L; Volkov P; Olsson AH; Hansen T; Pedersen O; Gjesing AP; Eiberg H; Tuomi T; Almgren P; et al. Blood-Based Biomarkers of Age-Associated Epigenetic Changes in Human Islets Associate with Insulin Secretion and Diabetes. *Nat Commun* 2016, 7, 11089 10.1038/ncomms11089. [PubMed: 27029739]
- (127). Constância M; Hemberger M; Hughes J; Dean W; Ferguson-Smith A; Fundele R; Stewart F; Kelsey G; Fowden A; Sibley C; et al. Placental-Specific IGF-II Is a Major Modulator of Placental and Fetal Growth. *Nature* 2002, 417 (6892), 945–948. 10.1038/nature00819. [PubMed: 12087403]
- (128). Munk S; Refsgaard JC; Olsen JV Systems Analysis for Interpretation of Phosphoproteomics Data. In *Phospho-Proteomics; Methods in Molecular Biology*; Springer, New York, NY, 2016; pp 341–360. 10.1007/978-1-4939-3049-4_23.
- (129). Landry CR; Levy ED; Michnick SW Weak Functional Constraints on Phosphoproteomes. *Trends Genet* 2009, 25 (5), 193–197. 10.1016/j.tig.2009.03.003. [PubMed: 19349092]
- (130). Fedorova L; Gatto-Weis C; Smaili S; Khurshid N; Shapiro JJ; Malhotra D; Horrigan T Down-Regulation of the Transcription Factor Snail in the Placentas of Patients with Preeclampsia and in a Rat Model of Preeclampsia. *Reprod Biol Endocrinol* 2012, 10, 15 10.1186/1477-7827-10-15. [PubMed: 22360878]
- (131). Dobierzewska A; Palominos M; Irarrazabal CE; Sanchez M; Lozano M; Perez-Sepulveda A; Monteiro LJ; Burmeister Y; Figueroa-Diesel H; Rice GE; et al. NFAT5 Is Up-Regulated by Hypoxia: Possible Implications in Preeclampsia and Intrauterine Growth Restriction1. *Biology of Reproduction* 2015, 93 (1). 10.1095/biolreprod.114.124644.

- (132). Wen F; Tynan JA; Cecena G; Williams R; Múnera J; Mavrothalassitis G; Oshima RG Ets2 Is Required for Trophoblast Stem Cell Self Renewal. *Dev Biol* 2007, 312 (1), 284–299. 10.1016/j.ydbio.2007.09.024. [PubMed: 17977525]
- (133). Asanoma K; Kubota K; Chakraborty D; Renaud SJ; Wake N; Fukushima K; Soares MJ; Rumi MAK SATB Homeobox Proteins Regulate Trophoblast Stem Cell Renewal and Differentiation. *J. Biol. Chem* 2012, 287 (3), 2257–2268. 10.1074/jbc.M111.287128. [PubMed: 22123820]
- (134). Vorgia E; Zaragkoulias A; Peraki I; Mavrothalassitis G Suppression of Fgf2 by ETS2 Repressor Factor (ERF) Is Required for Chorionic Trophoblast Differentiation. *Molecular Reproduction and Development* 2017, 84 (4), 286–295. 10.1002/mrd.22780. [PubMed: 28244611]
- (135). Papadaki C; Alexiou M; Cecena G; Verykokakis M; Bilitou A; Cross JC; Oshima RG; Mavrothalassitis G Transcriptional Repressor Erf Determines Extraembryonic Ectoderm Differentiation. *Molecular and Cellular Biology* 2007, 27 (14), 5201–5213. 10.1128/MCB.02237-06. [PubMed: 17502352]
- (136). Kessler CA; Stanek JW; Stringer KF; Handwerger S ETS1 Induces Human Trophoblast Differentiation. *Endocrinology* 2015, 156 (5), 1851–1859. 10.1210/en.2014-1760. [PubMed: 25651508]
- (137). Donnison M; Broadhurst R; Pfeffer PL Elf5 and Ets2 Maintain the Mouse Extraembryonic Ectoderm in a Dosage Dependent Synergistic Manner. *Developmental Biology* 2015, 397 (1), 77–88. 10.1016/j.ydbio.2014.10.011. [PubMed: 25446535]
- (138). Yabe S; Alexenko AP; Amita M; Yang Y; Schust DJ; Sadovsky Y; Ezashi T; Roberts RM Comparison of Syncytiotrophoblast Generated from Human Embryonic Stem Cells and from Term Placentas. *Proc. Natl. Acad. Sci. U.S.A* 2016, 113 (19), E2598–2607. 10.1073/pnas.1601630113. [PubMed: 27051068]
- (139). Huang D; Guo G; Yuan P; Ralston A; Sun L; Huss M; Mistri T; Pinello L; Ng HH; Yuan G; et al. The Role of Cdx2 as a Lineage Specific Transcriptional Repressor for Pluripotent Network during the First Developmental Cell Lineage Segregation. *Sci Rep* 2017, 7 (1), 17156 10.1038/s41598-017-16009-w. [PubMed: 29214996]
- (140). Pirinen E; Soini Y A Survey of Zeb1, Twist and Claudin 1 and 4 Expression during Placental Development and Disease. *APMIS* 2014, 122 (6), 530–538. 10.1111/apm.12187. [PubMed: 24304426]

Figure 1.

a) Whole proteome summary of acquired spectra, peptides, and proteins. b) Hierarchical clustering, based on Euclidian distance, of the proteome data from E7.5 and E9.5 placenta. Three biological replicates were carried out for each timepoint. The gradient reflects normalized intensity values of E7.5 (positive values; green) relative to E9.5 (negative values; brown). c) Scatterplot showing proteins upregulated at E7.5 (green) and at E9.5 (brown), based on a fold change of $\log_2(1.2)$ (upregulated at E7.5) or $-\log_2(1.2)$ (upregulated at E9.5) and a permutation-based q -value cutoff of < 0.05 . d) Heatmap showing the top ten most significant Gene Ontology Biological Process (GOBP) terms associated with upregulated proteins at each timepoint. Color gradient represents the significance based on Benjamini-Hochberg q -value. E, embryonic day; UP, upregulated protein.

Figure 2. Overlap of upregulated proteins (UPs) and upregulated transcripts (UTs) for genes detected at both the protein and transcript levels at E7.5 (a) and at E9.5 (b). c) Heatmap showing the top ten most significant Gene Ontology Biological Process (GOBP) terms associated with genes upregulated at both the protein and transcript levels at each timepoint (purple overlap in a and b). Color gradient represents the significance based on Benjamini-Hochberg q -value. E, embryonic day.

Figure 3.

a) Phosphoproteome summary of acquired spectra, peptides, and proteins. b) Hierarchical clustering, based on Euclidian distance, of the phosphoproteome data from E7.5 and E9.5 placenta. Three biological replicates were carried out for each timepoint. The gradient reflects normalized intensity values of E7.5 (positive values; yellow) relative to E9.5 (negative values; green). c) Number of unique phosphopeptides with 1 (singly), 2 (doubly), or 3 (triply) or more phosphorylation events. d) Number of unique phosphorylation events on Serines (S), Threonines (T), and Tyrosines (Y). The pie charts in c) and d) represent data from all Class I phosphosites in the filtered dataset (6,161 phosphosites).

Figure 4.
a) Proportion of previously characterized (dark green) and uncharacterized (light green) phosphosites in the phosphoproteome dataset, based on PhosphoSitePlus¹²⁸. b) Transcription factors implicated in placental processes with previously unknown phosphorylation events, where the phosphorylated amino acid is conserved in human (red). Underlined phosphosites were previously unknown in human as well as mouse. Other conserved amino acids are shown in dark green letters, and non-conserved amino acids are shown in light green letters. E, embryonic day.

Table 1.

Genes that are upregulated only at the protein level at E7.5 (using stringent criteria) and are associated with the “locomotion” Gene Ontology term are shown and are predicted to have a role in placental cell migration. For each gene, we determined if it has a known role related to cell migration or trophoblast migration.

Gene	Known related role	Known role in trophoblast migration?
Fermt3	Cancer cell invasion ^{64,65} and natural killer cell migration ⁶⁶	No
Atp8a1	Cancer cell invasion ⁵⁴ and ovarian cell migration ⁵³	No
Tspo	Cancer cell invasion ^{67,68}	No
Coro1a	Neutrophil ⁵⁵ and lymphocyte ⁵⁶ migration	No
Gpx1	Cancer cell invasion ^{69,70}	No
Hyal2	Cancer cell invasion ^{71,72}	No
Lsp1	Cancer cell invasion ⁷³ and macrophage migration ⁷⁴	No
Usp33	Cancer cell invasion ^{57,58}	No
Prkca	Cancer cell invasion ^{75,76}	No
Rras	Breast epithelial cell migration ⁷⁷ and endothelial cell adhesion ⁷⁸	No
Snca	Cancer cell invasion ^{79,80}	No
Stx4a	Cancer cell invasion ⁸¹ and macrophage migration ⁸²	No
Slirp	Cancer cell invasion ⁸³	No
Pf4	Neutrophil ⁸⁴ , monocyte ⁸⁵ , and cancer cell ^{86,87} migration	No
Plgrkt	Monocyte migration ^{88,89}	No
Ppbp	Cancer cell invasion ^{90,91}	No
Golph3	Cancer cell invasion ⁹²	No
Rps6kb1	Cancer cell invasion ⁹³	No
Lamb2	Astrocyte migration ⁹⁴	No
Sord	Cancer cell invasion ⁹⁵	No
Syk	Cancer cell invasion ⁹⁶⁻⁹⁸	No
Apoa1	Macrophage migration ^{99,100}	No
Anxa1	Cancer cell invasion ¹⁰¹ and myoblast migration ¹⁰²	No
Mpp1	Neutrophil migration ¹⁰³	No
Cd34	Cancer cell invasion ¹⁰⁴	No direct role known (involved in lumen formation by invasive trophoblasts ¹⁰⁵)
Col3a1	Cancer cell invasion ^{106,107}	No direct role known (highly expressed in extracellular matrix ¹⁰⁸⁻¹¹⁰)
Gab1	Cancer ¹¹¹ and epithelial ¹¹² cell invasion	No direct role known (though it has been implicated in trophoblast invasion ¹¹³)
Dcn	Cancer cell invasion ¹¹⁴	No direct role known (but expressed in invasive trophoblast cells in different stages/conditions of placentation ^{115,116})
Tgfb1	Cancer cell invasion ¹¹⁷	Yes ¹¹⁸⁻¹²¹ . Inhibits ^{118,119} or promotes ^{120,121} invasion.
Chmp3	No known role in migration	-

Table 2.

Genes that are upregulated only at the protein level at E9.5 (using stringent criteria) and are associated with the “liver development” Gene Ontology term are shown and are predicted to have a role in placental metabolism. For each gene, we determined if it has a known role related to metabolism or specifically placental metabolism.

Gene	Known related role	Known involvement in placental metabolism?
Rps6ka1	Insulin signaling ¹²⁴	No
Upf2	Liver metabolism ¹²⁵	No
Gnpnat1	Insulin signaling ¹²⁶	No
Igf2r	Fetal growth ¹²² , insulin resistance ¹²³	Implicated ^{116,127} . Receptor for Igf2, inhibiting its activity. Igf2 promotes nutrient transport to the fetus.
Rpl32	No known role in metabolism	-
Tgfbr3	No known role in metabolism	-
Tyms	No known role in metabolism	-
Pkd2	No known role in metabolism	-